Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial In Progress
676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)